Evaluation of potential complication of interstitial lung disease with abemaciclib and palbociclib treatments

BACKGROUND: Various cyclin‐dependent kinase 4/6 (CDK4/6) inhibitors have demonstrated promising anti‐tumor effects. The Japanese Ministry of Health, Labour and Welfare has issued a warning about interstitial lung diseases as an adverse effect of CDK4/6 inhibitors. However, a large‐scale evaluation o...

Descripción completa

Detalles Bibliográficos
Autores principales: Nawa, Hideki, Niimura, Takahiro, Yagi, Kenta, Goda, Mitsuhiro, Zamami, Yoshito, Ishizawa, Keisuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789605/
https://www.ncbi.nlm.nih.gov/pubmed/33939324
http://dx.doi.org/10.1002/cnr2.1402

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789605/
https://www.ncbi.nlm.nih.gov/pubmed/33939324
http://dx.doi.org/10.1002/cnr2.1402

Ejemplares similares